| Inclusion Criteria: | 1) Patients must have histologically or cytologically confirmed diagnosis of chondrosarcoma, extra-skeletal myxoid chondrosarcoma, or alveolar soft part sarcoma.
2) Patients may have had prior chemotherapy, but if the patient has had three or more forms of prior chemotherapy for metastases, the patient's clinical course should be discussed with the medical monitor or study chairman before the patient is enrolled on study.
3) Patients must have progression of disease by Choi criteria.
4) ECOG performance status 0-1. Patients with ECOG PS of 2 may be admitted with approval from the study chairman. Patients with a PS of 2 must meet criterion 1 and must be comfortable with the possibility of a transient period of tumor growth during the first weeks following the initiation of perifosine treatment.
5) At least 13 years of age.
6) Patients must have measurable disease. Patients who have brain metastases that have not progressed for at least 2 months following surgery or radiotherapy will be considered after discussion with the medical monitor.
7) Patients must have a life expectancy of more than 3 months.
8) Patients must have a normal organ and marrow function, unless in the opinion of the treating investigator, the abnormality is related to tumor, and the study chairman or medical monitor agree the abnormality is unlikely to affect the safety of perifosine use. Normal organ and marrow function is described below: HCT > 28% (with or without growth factor support), creatinine less than or equal to 2.5 mg/dl, total bilirubin < 1.5 x upper limit of normal and transaminase less than or equal to 2.5 x upper limit of normal.
9) Patients must have recovered from acute toxicity related to prior therapy, including surgery or radiotherapy to grade less than or equal to 1 (excluding alopecia ) at the time of enrollment.
10) Patients must be able to ingest oral medications or to obtain them through a gastrostomy tube.
11) Female patients who are pregnant or lactating are ineligible. All females of childbearing potential must have a negative urine or serum pregnancy test within 72 hours of treatment. Men and women of childbearing potential must agree to employ adequate contraception to prevent pregnancy while on therapy and for four weeks after the completion of treatment.
12) Patients must have the ability to understand and the willingness to sign a written informed consent document. |